Why the study?
What is the recommended antiplatelet and anticoagulant strategy for patients requiring chronic anticoagulation who undergo coronary stenting?
What is the recommended antiplatelet and anticoagulant strategy for patients requiring chronic anticoagulation who undergo coronary stenting?
Answers are grounded in this paper and cite their sources.
For patients on chronic anticoagulation undergoing coronary stenting, avoiding drug-eluting stents and using 1 month of triple therapy followed by lifelong aspirin and warfarin is recommended.
Dual antiplatelet therapy is standard treatment following coronary stent implantation. An important minority of patients also require chronic anticoagulation, most commonly for atrial fibrillation. There are no prospective trials to guide the selection of therapy in this situation. In this paper we review the available data and present practice recommendations. It appears that in patients who are not at high risk of bleeding, and in whom both coronary stenting and anticoagulation are considered necessary after careful consideration, drug eluting stents should be avoided as much as possible. Triple therapy with aspirin, clopidogrel and warfarin for one month, followed by the combination of aspirin and warfarin for life is the most reasonable approach.
No takes yet. Share an insight, caveat, or question.
Zahger et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: